The Latest Breaking News from gene editing

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.…

A new study from Stanford Medicine shows how a gene editing tool identified a gene to knock out that could promote activation of neural stem cells.

A geneticist recently discovered the gene that accounts for prickliness across a variety of plants, including roses.

As any avid gardener will tell you, plants with sharp thorns and prickles can leave you looking like you’ve had a run-in with an angry cat. Wouldn’t it be nice to rid plants of their prickles entirely but keep the tasty fruits and beautiful flowers?

The societal implications of this technology are still vast. And researchers can already start exploring the ethics by engaging communities well ahead of time.

Why ethical discussions with the target communities should happen sooner rather than later

With their primary goal to advance scientific knowledge, most scientists are not trained or incentivized to think through the societal implications of the technologies they are developing. Even in genomic medicine, which is geared toward benefiting future patients, time and funding pressures make real-time ethics oversight difficult.

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.